Patents by Inventor Samuel Alexander STRATFORD

Samuel Alexander STRATFORD has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monohydrate and crystalline forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[1,5-a]pyrazin-8-one
    Patent number: 12006319
    Abstract: The present disclosure relates to crystalline polymorph forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazol[1,5-a]pyrazin-8-one.
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: June 11, 2024
    Assignee: Cardurion Pharmaceuticals, Inc.
    Inventors: Suzanne Buttar, Mateusz Pitak, Adam Ross Patterson, Samuel Alexander Stratford, Ioana Sovago, Jun Xu, Peng Zhou, Haojuan Wei, Kuangchu Dai
  • FORMS AND COMPOSITIONS OF INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20230167132
    Abstract: The present invention provides solid forms of compound (1) and compositions thereof which are useful as inhibitors of Plasma Kallikrein (pKal) and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: April 16, 2021
    Publication date: June 1, 2023
    Inventors: Suresh Kumar Tipparaju, Jeffrey Scott DePue, Helge Alfred Reisch, Samuel Alexander Stratford, Joseph Stephen Harris, Nikolaos Papaioannou, Sarah Jocelyn Fink
  • Sodium Salt Of N-((1,2,3,5,6,7-Hexahydro-S-Indacen-4-Yl) Carbamoyl) -1 -Isopropyl-1 H-Pyrazole-3-Sulfonamide
    Publication number: 20210315862
    Abstract: The present invention relates to a sodium salt of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide and to hydrates, solvates and polymorphic forms thereof. The present invention further relates to pharmaceutical compositions comprising this compound and the use of this compound in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: March 9, 2021
    Publication date: October 14, 2021
    Inventors: David MILLER, Angus MACLEOD, Susana DEL RIO GANCEDO, Samuel Alexander STRATFORD
  • MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE
    Publication number: 20210107911
    Abstract: The present disclosure relates to crystalline polymorph forms of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazol[1,5-a]pyrazin-8-one.
    Type: Application
    Filed: December 2, 2020
    Publication date: April 15, 2021
    Inventors: Suzanne BUTTAR, Mateusz PITAK, Adam Ross PATTERSON, Samuel Alexander STRATFORD, Ioana SOVAGO, Jun XU, Peng ZHOU, Haojuan WEI, Kuangchu DAI
  • Sodium salt of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide
    Patent number: 10973803
    Abstract: The present invention relates to a sodium salt of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide and to hydrates, solvates and polymorphic forms thereof. The present invention further relates to pharmaceutical compositions comprising this compound and the use of this compound in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Grant
    Filed: April 16, 2020
    Date of Patent: April 13, 2021
    Assignee: Inflazome Limited
    Inventors: David Miller, Angus Macleod, Susana Del Rio Gancedo, Samuel Alexander Stratford
  • SODIUM SALT OF N-((1,2,3,5,6,7-HEXAHYDRO-S-INDACEN-4-YL)CARBAMOYL)-1 -ISOPROPYL-1 H-PYRAZOLE-3-SULFONAMIDE
    Publication number: 20200237723
    Abstract: The present invention relates to a sodium salt of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1H-pyrazole-3-sulfonamide and to hydrates, solvates and polymorphic forms thereof. The present invention further relates to pharmaceutical compositions comprising this compound and the use of this compound in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.
    Type: Application
    Filed: April 16, 2020
    Publication date: July 30, 2020
    Inventors: David MILLER, Angus MACLEOD, Susana DEL RIO GANCEDO, Samuel Alexander STRATFORD